Australia markets close in 3 hours 14 minutes
  • ALL ORDS

    7,650.50
    -30.80 (-0.40%)
     
  • ASX 200

    7,339.90
    -30.30 (-0.41%)
     
  • AUD/USD

    0.7294
    -0.0005 (-0.07%)
     
  • OIL

    73.04
    -0.26 (-0.35%)
     
  • GOLD

    1,751.30
    +1.50 (+0.09%)
     
  • BTC-AUD

    60,852.07
    +504.09 (+0.84%)
     
  • CMC Crypto 200

    1,110.67
    +1.75 (+0.16%)
     
  • AUD/EUR

    0.6210
    -0.0001 (-0.01%)
     
  • AUD/NZD

    1.0324
    +0.0010 (+0.10%)
     
  • NZX 50

    13,283.29
    -22.63 (-0.17%)
     
  • NASDAQ

    15,316.58
    +140.07 (+0.92%)
     
  • FTSE

    7,078.35
    -5.02 (-0.07%)
     
  • Dow Jones

    34,764.82
    +506.50 (+1.48%)
     
  • DAX

    15,643.97
    +137.23 (+0.88%)
     
  • Hang Seng

    24,555.21
    +44.23 (+0.18%)
     
  • NIKKEI 225

    30,200.89
    +561.49 (+1.89%)
     

ReCode Therapeutics to Present Preclinical Data from mRNA-Based Program for Primary Ciliary Dyskinesia at the 2021 PCD on the Move Virtual Scientific Conference

·1-min read

MENLO PARK, Calif. & DALLAS, July 30, 2021--(BUSINESS WIRE)--ReCode Therapeutics (the "Company"), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced preclinical data from the Company’s inhaled mRNA-based molecular therapy program for primary ciliary dyskinesia will be presented in an oral and poster presentation at the 2021 PCD on the Move Virtual Scientific Conference, which is being held virtually on Thursday, August 5, 2021 at 11:45 am ET.

Archived replays of each presentation will be made available on the Company’s website following the presentations.

About ReCode Therapeutics

ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using powerful LNP delivery technology to target organs and tissues beyond the liver. The Company’s pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The Company is leveraging its proprietary LNP platform and nucleic acid technologies and utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells. For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210730005576/en/

Contacts

Media Contact:
Will Zasadny
Canale Communications, Inc.
will.zasadny@canalecomm.com
(619) 961-8848

Investor Contact:
Sarah McCabe
Stern Investor Relations
sarah.mccabe@sternir.com
IR@recodetx.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting